Last reviewed · How we verify
ABBV-932
ABBV-932 is a bispecific antibody that simultaneously engages CD3 on T cells and a tumor-associated antigen to redirect immune cells to kill cancer cells.
ABBV-932 is a bispecific antibody that simultaneously engages CD3 on T cells and a tumor-associated antigen to redirect immune cells to kill cancer cells. Used for Solid tumors (specific indications under investigation in phase 2).
At a glance
| Generic name | ABBV-932 |
|---|---|
| Sponsor | AbbVie |
| Drug class | Bispecific antibody, T-cell engager |
| Target | CD3 and tumor-associated antigen (specific target not publicly disclosed) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
As a T-cell engaging bispecific antibody, ABBV-932 bridges cytotoxic T lymphocytes to tumor cells by binding CD3 on T cells and a tumor antigen on cancer cells, thereby activating and redirecting T cells to recognize and eliminate malignant cells. This mechanism leverages the body's own immune system to target cancer more specifically than conventional approaches.
Approved indications
- Solid tumors (specific indications under investigation in phase 2)
Common side effects
- Cytokine release syndrome
- Immune-related adverse events
Key clinical trials
- Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder (PHASE2)
- A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult Participants (PHASE1)
- Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder (PHASE2)
- Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (PHASE2)
- Study to Assess the Adverse Events, Tolerability, and How Oral Doses of ABBV-932 Moves Through the Body in Healthy Adult Chinese Participants (PHASE1)
- A Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body When Given With Oral Itraconazole in Healthy Adult Participants (PHASE1)
- A Mass Balance Study of Oral [14C] ABBV-932 in Healthy Adult Male Participants (PHASE1)
- Study of Oral ABBV-932 Capsules to Evaluate Dopamine D2 and D3 Receptor Occupancy in Brain in Adult Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABBV-932 CI brief — competitive landscape report
- ABBV-932 updates RSS · CI watch RSS
- AbbVie portfolio CI